Asure Software Can Gain From Small Client Churn Of Bigger Rivals Like Adp, Paychex: Analyst
Barrington Research analyst Vincent A.
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell
• Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Baird Maintains Outperform on Equifax, Raises Price Target to $237
Baird analyst Jeffrey Meuler maintains Equifax (NYSE:EFX) with a Outperform and raises the price target from $223 to $237.
Equifax Q4 Adj. EPS $1.52 Beats $1.49 Estimate, Sales $1.20B Beat $1.18B Estimate
Equifax (NYSE:EFX) reported quarterly earnings of $1.52 per share which beat the analyst consensus estimate of $1.49 by 2.01 percent. This is a 17.39 percent decrease over earnings of $1.84 per share from the same period
Equifax Q4 EPS $1.52 Beats $1.49 Estimate, Sales $1.20B Beat $1.18B Estimate
Equifax (NYSE:EFX) reported quarterly earnings of $1.52 per share which beat the analyst consensus estimate of $1.49 by 2.01 percent. This is a 17.39 percent decrease over earnings of $1.84 per share from the same period
Fintech Firm Fidelity National Information Downsizes 2,600 Jobs As Part Of Restructuring: Report
Fidelity National Information Services, Inc (NYSE: FIS) has eliminated 2,600 staffers as new CEO Stephanie Ferris continues her strategic review.
Expert Ratings for Equifax
Analysts have provided the following ratings for Equifax (NYSE:EFX) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Wells Fargo Maintains Equal-Weight on Equifax, Raises Price Target to $210
Wells Fargo analyst Seth Weber maintains Equifax (NYSE:EFX) with a Equal-Weight and raises the price target from $165 to $210.
Goldman Sachs Maintains Neutral on Equifax, Raises Price Target to $212
Goldman Sachs analyst Andre Benjamin maintains Equifax (NYSE:EFX) with a Neutral and raises the price target from $187 to $212.
Benzinga’s Top Ratings Upgrades, Downgrades For January 6, 2023
Upgrades Piper Sandler upgraded the previous rating for Aligos Therapeutics Inc (NASDAQ:ALGS) from Neutral to Overweight. Aligos Therapeutics…